Viewing Study NCT06592105



Ignite Creation Date: 2024-10-26 @ 3:40 PM
Last Modification Date: 2024-10-26 @ 3:40 PM
Study NCT ID: NCT06592105
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-08-27

Brief Title: AI-enhanced Imaging Analysis to Predict Post-EVAR
Sponsor: None
Organization: None

Study Overview

Official Title: AI-enhanced Imaging Analysis for the Prediction of Post-operative Outcomes Following EVAR
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Abdominal aortic aneurysm AAA defined as a focal dilatation of the aorta is a life-threatening condition and has become a serious public health challenge worldwide associated with high rates of mortality and hospitalization Endovascular aortic repair EVAR requires long-term surveillance by a multidisciplinary team to detect and treat post-operative complicationsThis international multicentre retrospective observational study aims to use Artificial Intelligence-enhanced imaging analysis for the prediction of post-operative outcomes following EVAR The primary aim is to identify predictive factors and build prediction models of post-operative outcomes following eligible EVAR The secondary objective is to investigate morphological aortic changes and remodelling following EVAR

Screening for eligible patients will be done by a vascular specialist at each participating centers Only subjects fulfilling all the inclusion and none of the exclusion criteria will be accepted in the study

Inclusion criteria from clinical characteristics may encompass the following - patients who underwent elective EVAR for non-ruptured AAA for the first time - patients who underwent non-complex EVAR procedure with commercially available endografts with CE mark - patients with non-syndromic AAA or with non-infective AAA - patients aged more than 18 years old Inclusion criteria from CTA characteristics may encompass the following - patients for whom one pre-operative and at least one post-operative CTA within 1-year can be collected in DICOM format Detailed criteria for eligibility include the following - Pre-operative CTA should be performed maximum 6 months before the intervention - At least one post-operative CTA should be performed between 1 month and 12 months following the intervention - CTA needs to be contrast-enhanced with at least injection at arterial andor portal time - CTA should have a spacing no more than 1 mmPrimary outcome will be EVAR-related complications including endoleaks limb-occlusion and stent-graft migration Secondary outcomes will include in-hospital length of stay post-intervention re-interventions with indication for re-intervention and deaths all-cause and aneurysm-related deaths Outcomes will be investigated within 1 year and at the last follow-up of patients Morphological changes following EVAR will be analyzed and compared based on pre-operative and post-operative CTA images Images will be collected and analysed using the PRAEVAorta 2 software Nurea Anatomic features measured include the measurement of aneurysm volume diameters and diameters including AAA maximum diameter measurement of intraluminal thrombus and calcifications proximal and distal aneurysm neck lengths and diameters suprarenal and infrarenal angulation distal iliac landing zone length and diameter and iliac tortuosity index Based on the measurements aneurysm sac will be classified into three categories stable shrinkage expansionThe study will allow to identify predictive factors and develop predictive models of outcomes following eligible EVAR By leveraging two approaches traditional statistical analysis and AI-driven algorithms and providing AI-enhanced detailed imaging analysis of the morphological characteristics of AAA this study will allow a better understanding of pre-operative features predictive of the patients outcomes
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None